DEMULEN 1/50-21 (ethinyl estradiol; ethynodiol diacetate) by Pfizer. Approved for pregnancy. First approved in 1970.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
DEMULEN 1/50-21 is a combination oral contraceptive tablet containing ethinyl estradiol and ethynodiol diacetate, approved in 1970 for pregnancy prevention. It is a 21-day regimen tablet that works through hormonal suppression of ovulation and cervical mucus thickening. This product represents a legacy small-molecule hormonal formulation in a highly competitive contraceptive market.
Product is in late-stage lifecycle with minimal linked job postings, signaling a mature brand with likely reduced commercial investment and team size.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Working on DEMULEN 1/50-21 offers limited growth potential due to its approaching loss of exclusivity and zero linked job postings; career progression would depend on lateral moves to growth-stage contraceptive products or broader portfolio expansion within Pfizer's women's health franchise. This position is best suited for professionals seeking stability in a mature market segment or those preparing to transition to emerging contraceptive technologies.
Worked on DEMULEN 1/50-21 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.